Pharmaceuticals

Lung Cancer Drugs Market Forecast: How Big Will It Be by 2030?

February 16, 2026February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the lung cancer drugs market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Lung Cancer Drugs Market size between 2026 and 2035?

The lung cancer drugs market size has demonstrated significant growth in recent years. It is anticipated to increase from $52.98 billion in 2025 to $58.23 billion in 2026, at a compound annual growth rate (CAGR) of 9.9%. This historical expansion is largely due to factors such as high smoking prevalence, a rise in lung cancer incidence, extensive adoption of chemotherapy, the growth of oncology hospitals, and improved availability of generic cancer drugs.

The lung cancer drugs market is set for significant expansion in the coming years, with projections indicating a rise to $88.06 billion by 2030, propelled by a compound annual growth rate (CAGR) of 10.9%. This anticipated growth during the forecast period stems from factors such as the development of targeted and immunotherapy drugs, enhanced rates of lung cancer screening, escalating healthcare spending in oncology, an expanding aging population, and the wider approval of combination therapies. Prominent trends expected over the forecast horizon include a greater embrace of targeted lung cancer treatments, increased utilization of combination drug regimens, a heightened emphasis on addressing early-stage lung cancer, the broadening of personalized treatment approaches, and a rise in the hospital-based provision of oncology drugs.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2567&type=smp

Which Drivers Are Impacting Market Performance In The Lung Cancer Drugs Market?

The increasing incidence of lung cancer is projected to propel the expansion of the lung cancer drugs market moving ahead. As a life-threatening malignancy, lung cancer necessitates prompt and effective medical interventions, such as chemotherapy, targeted therapies, immunotherapies, and combined regimens, to enhance patient survival. This rise in lung cancer cases is largely attributable to environmental pollution, exposure to carcinogens, and genetic factors, which together lead to mutations in lung cells, even among individuals who do not smoke. The escalating prevalence of lung cancer thus bolsters the lung cancer drugs market by stimulating the need for more efficacious therapeutic options designed to extend life expectancy, slow tumor advancement, and elevate the overall quality of life for those affected. For example, in January 2023, the American Cancer Society, a US-based voluntary health organization focused on cancer eradication, estimated approximately 238,340 new lung cancer cases (comprising 117,550 in men and 120,790 in women) and around 127,070 lung cancer deaths (with 67,160 in men and 59,910 in women) for 2023. Consequently, the escalating prevalence of lung cancer is fueling the expansion of the lung cancer drugs market.

Which Segments Are Contributing To The Growth Of The Lung Cancer Drugs Market?

The lung cancer drugs market covered in this report is segmented –

1) By Drugs: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs

2) By Disease Type: Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)

3) By End User: Hospitals, Clinics, Other End-Users

How Are Emerging Trends Affecting The Progression Of The Lung Cancer Drugs Market?

Leading companies in the lung cancer drugs market are concentrating on innovative products and formulations, including chemotherapy-free combination therapies that target EGFR mutations. This focus aims to boost treatment effectiveness, decrease systemic toxicity, and elevate the quality of life for individuals with advanced non-small cell lung cancer (NSCLC). Such therapies facilitate precision oncology strategies by specifically inhibiting molecular pathways that fuel tumor growth. As an example, in August 2024, Johnson & Johnson, a US-based pharmaceutical company, secured U.S. FDA approval for Rybrevant plus Lazcluze. This was approved as a first-line, chemotherapy-free option for patients suffering from EGFR-mutated advanced NSCLC. The combination therapy is engineered to achieve dual inhibition of both EGFR and MET pathways, delivering improved anti-tumor activity while lowering exposure to the adverse effects of traditional chemotherapy. This significant approval underscores an evolving trend within the lung cancer market towards personalized, targeted treatment approaches that enhance patient outcomes and experience by lessening dependence on standard chemotherapy.

Who Are The Prominent Global Companies Shaping The Lung Cancer Drugs Market Landscape?

Major companies operating in the lung cancer drugs market are Bristol-Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Celgene Corporation, Mylan N.V., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ziopharm Oncology Inc., Menarini Group, AstraZeneca PLC, AbbVie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eli Lilly and Company Inc., Johnson & Johnson, Amgen Inc., Array BioPharma Inc., Astellas Pharma Inc., Clovis Oncology Inc., Eisai Co. Ltd., Exelixis Inc., Genentech Inc., Gilead Sciences Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., Kyowa Kirin Co. Ltd., Loxo Oncology Inc., MedImmune LLC

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Lung Cancer Drugs Market?

North America was the largest region in the lung cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the lung cancer drugs market during the forecast period. The regions covered in the lung cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Lung Cancer Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2567&type=smp

Browse Through More Reports Similar to the Global Lung Cancer Drugs Market 2026, By The Business Research Company

Lung Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Non Small Cell Lung Cancer Nsclc Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

Non Small Cell Lung Cancer Nsclc Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795